Brought to you by 
FoldRx completes $43mm Series B round
26 Oct 2012
Executive Summary
FoldRx (small-molecule therapeutics for protein misfolding diseases) raised $43mm in its Series B round that was led by Texas Pacific Group Ventures and Alta Partners. Novartis BioVenture Fund and existing investors HealthCare Ventures and Fidelity Biosciences also participated. The company will use the proceeds to continue clinical development of Fx1006A, its lead amyloid deposit inhibitor in Phase I trials to treat familial amyloid polyneuropathy and familial amyloid cardiomyopathy.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
FoldRx completes $43mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice